Introduction
Primary gastrointestinal non Hodgkin's lymphoma (PGI-NHL) represents the most common types of extranodal lymphoma and DLBCL is the most frequent histologic type. PGI-DLBCL is a relatively rare disease, accounting for only 1-4 % of those with gastrointestinal malignancies. The most frequent site is stomach followed by small intestine and ileocecal region [1] [2] [3] . Endoscopic examination combined with pathological biopsy is still the most important and reliable method for detection of PGI-DLBCL. Nowadays, there is still no consensus on its treatment, the majority of patients were treated with combined therapy (chemotherapy and radiotherapy, surgery plus chemotherapy, surgery plus chemotherapy, and radiotherapy).The majority of chemotherapeutic protocols was CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimens and/without rituximab [4] [5] [6] . Immunodeficiency is considered to be one of the most dangerous factors in NHL, with a greater risk of developing lymphoma with congenital or acquired immunodeficiency. Gene expression profiling (GEP) have provided crucial information as to the intrinsic heterogeneity of lymphoma cells and the role of the tumor microenvironment. The prognostic model based on gene expression in DLBCL indicates that the prognosis of patients not only dependent on the clinical parameters, but also on the gene regulation of tumor microenvironment [7, 8] . However, many of these risk factors are costly, difficult to perform and not easily interpreted. Therefore, prognostic models for PGI-DLBCL that are inexpensive, widely available and easily interpreted by clinicians are needed [9] . Lymphocyte is the main component of immune cells, which has important anti-tumor effect. It reflects both the immune status of the host and the degree of tumor progression. The systemic inflammation has been recognized as correlating with tumor progression and inflammatory markers have been reported to be useful for predicting the tumor prognosis. The monocytes and platelet are inflammatory markers [4, 10, 11] . Previous studies [7] [8] [9] [10] [11] showed that ALC, AMC, PLT, LMR and PLR were prognostic factors for many malignancies. In another study, we found that the LMR could be an efficient prognostic factor for these newly-diagnosed MM patients with extramedullary invasion. However, there are limited data by now to demonstrate their usefulness for PGI-DLBCL. The aim of this study was to determine whether ALC, AMC, PLT, LMR and PLR were prognostic factors for PGI-DLBCL.
Patients and Methods

Patients
We carried out a retrospective study of 173 patients with PGI-DCBCL diagnosed at Tianjin Medical University Cancer Institute and Hospital in March 2009-February 2015. All patients met the following criteria: no previous treatment, no previous history of malignancy, or immunosuppression. There were 111 males and 62 females. The median age was 51 years (range 12-90 years), median follow-up time was 44 months (range 7-89 months). Clinical parameters included patient age, gender, primary site, GCB or nGCB, systemic B symptoms, Lugano stage, IPI, Hb, ALC, AMC, PLT, LDH, b2m, surgery or not. Definitions of response criteria, overall survival, progression-free survival, and time to progression were based on the guidelines from the International Harmonization Project on Lymphoma. OS was defined as the time from diagnosis of PGI-DLBCL to death from any cause. PFS was defined as time from diagnosis to lymphoma relapse, progression or death of any cause.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows (Version 17.0). The time-dependent receiver operating characteristic (ROC) curve analysis was used to determine the best cut-off value of preoperative ALC, AMC, LMR, PLR. Survival was analyzed by the KaplanMeier and compared by different groups using the log-rank test and the Cox proportional hazards model. p \ 0.05 was considered statistically significant.
Results
Selection of the Best Cut-Off Value of ALC, AMC, LMR, PLR for PGI-DCBCL Patients
The cutoff points of ALC, AMC, LMR and PLR were selected by the receiver operating characteristics curves analysis. The best cutoff value of ALC was 1.5 9 10 9 /L, with an area under the curve (AUC) value of 0.663 (95 % CI 0.578-0.748, p \ 0.001) (Fig. 1a) . The most discriminative cutoff value of AMC was 0.5 9 10 9 /L, with an AUC value of 0.629 (95 % CI 0.543-0.715, p = 0.004) (Fig. 1b) . ROC curve analysis in 173 patients established 2.5 as the cutoff point of LMR with an AUC of 0.718 (95 % CI 0.638-0.799, p \ 0.001) (Fig. 1c) and established 170 as the cutoff point of PLR with an AUC of 0.590 (95 % CI 0.500-0.679, p = 0.004) (Fig. 1d) .
In Univariate Analysis: Prognostic Significance of Clinical Parameters
We retrospectively analyzed the prognostic significance of all parameters in 173 patients. We found that patients with an (Fig. 2h) . On univariate analysis, both the OS and PFS outcomes were associated with age [60 years, systemic B symptoms, stage III-IV, Hb B 11 g/ dL, IPI [ 2 score, high LDH, high b2m, no surgery. However, gender, primary site, PLT and immune subtype are in no way associated with the OS and PFS outcome (Table 1) .
Relationship Between ALC, AMC, LMR, PLR and Other Prognostic Factors
The clinical features of the patients with an ALC C 1.5 9 10 9 /L and those with an ALC \ 1.5 9 10 9 /L are summarized in Table 2 . Eighty-seven patients (50.3 %) IPI international prognostic index, Hb hemoglobin, ALC the absolute lymphocyte count, AMC absolute monocyte count, PLT platelet count, LMR lymphocyte-monocyte ratio, PLR platelet-lymphocyte ratio, LDH lactate dehydrogenase, b2m b 2-microglobulin, OS overall survival, PFS progression-free survival had an ALC C 1. 
Multivariate Analysis for OS and PFS Outcomes
We used Cox Regression analysis to evaluate the prognostic impact of LMR at diagnosis on the survival of PGI-DLBCL patients. Parameters included in the multivariate survival analysis are shown in Table 5 . This study showed that LMR was identified as an independent prognostic factor for OS and PFS. Age was shown to be independent prognostic factors for OS, while LDH, ALC were independent risk factors for PFS.
Discussion
Primary gastrointestinal diffuse large B-cell lymphoma is the most common extranodal site involved by diffuse large B-cell lymphoma [12] . The international prognostic index IPI international prognostic index, Hb hemoglobin, ALC the absolute lymphocyte count, LDH lactate dehydrogenase, b2m b 2-microglobulin (IPI) developed for DLBCL is, at present, the most valuable and widely used for the stratification of almost all subtypes of NHL. Because of ignoring the host adaptive immunity and tumor microenvironment which play an important role in the pathogenesis of lymphoma, the guidance mode cannot really distinguish high-risk populations with the use of rituximab. Gene expression profiling studies in NHL, shows that gene expression by tumor-infiltrating lymphocytes and myeloid-derived cells can predict clinical outcomes [9, 13, 14] . Therefore, these findings give us evidence that peripheral lymphocyte counts and monocyte counts, which were biomarkers of host immunity and the tumor microenvironment, can predict the prognosis of patients. Our study showed that the correlations of ALC, AMC, LMR and PLR levels with the prognosis of PGI-DLBCL.
A total of 173 patients in this study,We found that lower ALC and LMR, higher AMC and PLR were indicators of poor prognosis.
Lymphocytes act as basic components of the immune system. Reducing lymphocytes in the blood and in the tumor stroma lead to a down regulation of the immune response against the tumor. Lymphopenia before initiation of systemic treatment was noted to be a negative of clinical outcome in solid malignancies as well as in hematological malignancies [7, 15] .The important contribution of T and NK cells in immune surveillance, illustrated by occurrence of post-transplant lymphoproliferative disease and HIVassociated lymphomas. Lymphocytopenia was found to be a strong negative prognostic marker which correlated strongly with the disease burden, patients' fitness and overall outcome. Thus, lymphopenia is considered as a sign of the host immune deficiency [16] . In our study, the univariate analysis of prognostic parameters showed that ALC was significantly associated with OS and PFS. In multivariate analysis, ALC was related with PFS, but not associated with the OS.
Monocyte, which is an important source of soluble mediators, plays an important role in suppress adaptive immunity and promotes angiogenesis, invasion, migration, and tumor growth [17, 18] . In addition, monocyte-derived cells may also provide nutrition factors that directly promote the growth and survival of malignant lymphocytes. Peripheral blood monocytes and their progeny within the IPI international prognostic index, Hb hemoglobin, LMR lymphocyte-monocyte ratio, LDH lactate dehydrogenase, b2m b 2-microglobulin tumor microenvironment express the T-cell co-inhibitory ligand B7-H1 (PD-L1), which stimulates the expansion of suppressive regulatory T cells. Therefore it is not surprising that peripheral blood monocytosis is adverse prognostic factor in various tumors [15] [16] [17] . Platelets, an important factor in thrombosis, has been known as mediate cancer IPI international prognostic index, Hb hemoglobin, ALC the absolute lymphocyte count, AMC absolute monocyte count, LMR lymphocyte-monocyte ratio, PLR platelet-lymphocyte ratio, LDH lactate dehydrogenase, b2m b 2-microglobulin, OS overall survival, PFS progression-free survival, HR hazard ratio Indian J Hematol Blood Transfus (July-Sept 2017) 33(3):333-341 339 cell growth, dissemination and angiogenesis. Activated platelets are able to interact with tumor cells through paracrine signaling or direct contact, thus promoting cancer cell growth and survival. Clinical data also suggested that elevated platelet number was related with poor prognosis in many types of tumors [4, [18] [19] [20] [21] [22] . We retrospectively analyzed all parameters in 173 patients and found that the univariate analysis of prognostic parameters showed that AMC was significantly associated with OS and PFS. However, in multivariate analysis, AMC has less significance of OS and PFS. The LMR as a surrogate marker of host immunity (ALC) and tumor-microenvironment (AMC) has been reported as prognostic factor of clinical outcomes in DLBCL. Our study showed that LMR is also an effective prognostic factor in PGI-DLBCL patients. Besides,we found PLR's significant role in the diagnosis of all kinds of tumors [18] [19] [20] [21] [22] , PLR was generally high in tumor patients and patients with higher value of PLR had lower survival. Our findings suggested that patients with an PLR [ 170 in PGI-DLBCL might be lower OS and PFS.
The gene expression profiling (GEP) of lymphoma cells is another Important factor that influences the prognosis of PGI-DLBCL patients. According to GEP,three gene-expression subgroups-germinal-center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 diffuse large-Bcell lymphoma-were demonstrated [23] . Although a quite powerful tool that reveals wide-ranging biological information about tumor biology, gene expression profiling is not easily available in most laboratories. Immunohistochemistry stain is readily available and routinely performed. It is used to divided DLBCL into GCB and non-GCB groups [24] . Studies have reported that GCB phenotype has a significantly better prognosis compared to patients with the non-GCB phenotype [25] .In our study, both PFS and OS data were not significantly different between the two groups.
Conclusion
In summary, although the means of evaluating PGI-DLBCL prognosis are varied, but these tools have some flaws. IPI totally overlooked the host immunity and tumor microenvironment which are important to the pathogenesis of lymphoma. The price of immunohistochemical stain is very high and sampling method is difficultly. Positron Emission Tomography/Computed Tomography (PET/CT) is not only expensive but also increases the number of false positive. The Peripheral blood cell count, readily available, inexpensive, objective data, is expected to become a means to evaluate the prognosis of PGI-DLBCL patients.
